Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 5/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | NOTCH1 | P46531 | 6/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.50 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.50 |
| ▸ | NOTCH3 | Q9UM47 | 4/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300057 | 0.84 | CCKBR (0.59) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4412193 | 0.83 | CCKBR (0.60) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL6300483 | 0.83 | CCKBR (0.55) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4414763 | 0.81 | CCKBR (0.83) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL6301977 | 0.81 | CCKBR (0.83) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL7067691 | 0.81 | CCKBR (0.83) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4412770 | 0.79 | CCKBR (0.66) | CCKBR | |
| SCHEMBL4411431 | 0.77 | CCKBR (0.70) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL6301543 | 0.77 | CCKBR (0.62) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4989079 | 0.77 | CCKBR (0.62) | CCKBRKCNH2NOTCH1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838455-B2 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1093372-A4 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6696438-B2 | AMYLOID PRECURSOR PROTEIN ANTAGONISTS, 3-((N'-(3-PYRIDINOYL)-L -ALANINYL)-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE, USED FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-28 | — | — | US | disclosed |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552013-B1 | For therapy of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6528505-B1 | Treating Alzheimer's disease;5-(S)-(N'-(L-prolyl)-L-alaninyl)-amino-7-methyl-5,7-di hydro-6H- dibenz(b,d)azepin-one | ELAN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1093372-A1 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999066934-A1 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | CCKBR 147/4885KCNH2 4759/4885NOTCH1 737/4885 |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | CCKBR 537/4885KCNH2 4774/4885NOTCH1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.